Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1382_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
11 Мб
Скачать
☆
ENDOCRINE SURGERY
Table 16.5. Differential diagnosis of hypercalcemia
Category Condition Mechanism Indication for Diagnosis Malignancy Solid tumor (PTHrP): lung, kidney, squamous cell
carcinomas of the head and neck/esophagus/ female genital tract
Osteoclastic metastasis: breast, prostate Hematological: multiple myeloma, lymphoma,
leukemia
Hypercalcemic cytokines: interleukin 1 and 6, tumor
necrosis factor alpha, prostaglandins
Excess PTH Primary hyperparathyroidism
Sporadic or familial (MEN I and 2A)
Tertiary hyperparathyroidism
Increased
bone turnover
Excess
vitamin D
(Calcitriol induced)
Renal failure Secondary hyperparathyroidism
Iatrogenic Lithium
Familial Familial hypocalciuric hypercalcemia
Miscellaneous Addisonian crisis or glucocorticoid deficiency Lack of PTH
Hyperthyroidism Immobilization
Paget’s disease Acute intermittent porphyria AIDS/HIV Granulomatous disease (e.g., Sarcoidosis,
tuberculosis, histoplasmosis)
Milk alkali syndrome Aluminium intoxication
Vitamin A intoxication (analogs used to treat acne) Thiazide diuretics Vitamin D intoxication Tamoxifen Theophylline Salicylic acid intoxication
Idiopathic hypercalcemia of infancy
Osteolytic factors:
PTHrP
IL-1 IL-6 TNF Prostaglandins Calcitriol
Increased intestinal
and renal Ca
absorption Osteolysis Ca release from
skeleton
Increased 1,25-
dihydroxylated
vitamin D
Decrease in calciuria Impaired renal function
Increased PTH Increased bone
turnover Excess vitamin D
CaSR defect causing
decrease in
calciuria ?PTHrP
antagonist
Staging for malignancy
(CT, skeletal X-ray,
bone scan) Elevated tumor markers Elevated PTHrP and
calcitriol Low PTH
Raised PTH and Ca
Low PTH History
(X-rays, thyroid function,
HIV serology)
X-ray of lungs Serology and
microbiology Raised calcitriol
History
Medication history
Hypocalciuria PTH normal or high
Ca/creatinine clearance
<0.01 Age and exclusion of
other causes Low PTH Raised PTHrP Glucocorticoid tests Low PTH
230
of bone assessed in the region of interest and gives a value for BMD in that region. BMD measurements correlate with load-bearing capacity of the hip and spine and with the risk of fracture [80]. The measurements are expressed as a T-score and a Z-score which
represent the patient’s bone density in standard deviations from their respective controls [81].
The T-score is a measurement of bone den­sity compared with that of 30-year-old Cauca­sian adult of the same gender with peak bone mass and is expressed in standard deviations
231
PRESENTATION AND DIAGNOSIS OF PRIMARY HYPERPARATHYROIDISM
from the control value of 0. A score within one standard deviation (+1 to –1) is considered normal, between –1 and –2.5 is classified as osteopenia and a score below –2.5 is classified as osteoporosis. The T-score is used to estimate
Fig. 16.3. DEXA scan of spine with severe osteoporosis.
the risk of developing a fracture. Established osteoporosis is defined as a T-score below –2.5 and a history of at least one osteoporotic frac­ture (Figs. 16.3 and 16.4). The Z-score is a cal­culation of bone density compared with patients
Fig. 16.4. DEXA scan of right femur with osteoporosis.
232
ENDOCRINE SURGERY
of the same age group, size, and gender and is therefore usually more relevant to clinical deci­sion making in patients with pHPT.
Bone mineral density can be followed over time as a response to treatment or for surveil­lance as well as being a research end point. Newer tools aimed at measuring bone strength, in particular quantitative ultrasound, are also being studied. Indeed, quantitative ultrasound of the heel appears to be almost as predictive of hip fracture and all nonvertebral fractures as DEXA at the femoral neck [81].
Conclusions
Primary hyperparathyroidism is not as uncom­mon as thought in the past. It is now diagnosed more frequently and at an earlier stage in its natural history. Whilst asymptomatic disease may still be present, most patients present with a subtle 21
st
century version of the disease that is, however, far from innocuous. The diagnosis requires a thorough understanding of calcium metabolism and accurate biochemical investiga­tions. Only once the diagnosis of pHPT has been unequivocally made, can definitive treatment with surgery be considered.
References
1. Organ, C. The history of parathyroid surgery, 1850–1996; the excelsior surgical society 1998 Edward D Churchill lecture. J Am Coll Surg. 2000;191: 284–99.
2. Clark OH, Duh QY. Primary hyperparathyroidism. A surgical perspective. Endocrinol & Metab Clin N Am. 1989;18(3):701–14, 284–99.
3. Adami S, Marocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002;17(suppl. 2):N18–23.
4. Melton JL. The epidemiology of primary hyperparathyr­oidism in North America. J Bone Miner Res. 2002;17(suppl.
2):N12–7.
5. Anonymous. Proceedings of the NIH Consensus Devel­opment Conference on diagnosis and management of asymptomatic primary hyperparathyroidism. Bethesda, Maryland, October 29–31, 1990. J Bone Miner Res. 1991;6(suppl 2):S1–166.
6. Heath H, Hodgson SF, Kennedy MA. Primary hyperpar­athyroidism: incidence, morbidity and economic impact in a community. N Eng J Med. 1980;302:189.
7. Lundgren E, Rastad J, Thrufjell E, A˚kerstr¨om G, Ljunghall S. Population-based screening for primary hyperparathyroidism withserumcalciumandpara­thyroid hormone values in menopausal women. Sur­gery. 1997;121(3):287–94.
8. Lundgren E, Hagstrom EG, Lundin J, Winnerback K, Roos J, Ljunghall S, Rastad J. Primary hyperparathyr­oidism revisited in menopausal women with serum calcium in the upper normal range at population­based screening 8 years ago. World J Surg. 2002; 26(8):931–6.
9. Stephen AE, Chen KT, Milas M, Siperstein AE. The coming of age of radiation-induced hyperparathyroid­ism: evolving patterns of thyroid and parathyroid dis­ease after head and neck irradiation. Surgery. 2004;136(6):1143–53.
10. Hundley JC, Woodrum DT, Saunders BD, Doherty GM, Gauger PG. Revisiting lithium-associated hyperpar­athyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery. 2005;138(6):1027–31.
11. Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S, Cianferotti L, Vignali E, Viacava P, Berti P, Mariotti S, Pinchera A, Marcocci C. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol. 2006;64(2):146–52.
12. Benson L, Ljunghall S, A˚kerstr¨om G,¨Oberg K. Hyper­parathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1 (MEN1). Am J Med. 1987;82:731–737.
13. Malone JP, Srivastava A, Khardori R. Hyperparathyr­oidism and multiple endocrine neoplasia. Otolaryngol Clin N Am. 2004;37(4):715–36.
14. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe – nationwide cohort analysis on mortality from nonmalignant causes. J Bone Min Res 2002;17(Suppl 2):N68–74.
15. Ljunghall S, Per Hellman P, Rastad J, A˚kerstr¨om G. Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture. World J Surg. 1991;15(6):681–7.
16. Jacob JJ, John M, Thomas N, Chacko A, Cherian R, Selvan B, Nair A, Seshadri M. Does hyperparathyroid­ism cause pancreatitis? A South Indian experience and a review of published work. ANZ JSurg. 2006;76(8):740–4.
17. Carella MJ, Gossain VV. Hyperparathyroidism and pregnancy: case report and review. J Gen Int Med. 1992;7(4):448–53.
18. Clark OH, Wilkes W, Siperstein AE, Duh QY. Diagnosis and management of asymptomatic hyperparathyroid­ism: safety, efficacy, and deficiencies in our knowledge. J Bone Min Res. 1991;6(Suppl 2):S135–42.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short­form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
20. Burney RE, Jones KR,Peterson M, Christy B, Thompson NW. Surgical correction of primary hyperparathyroid­ism improves quality of life. Surgery. 1998;124:987–92.
21. Caillard C, Sebag F, Mathonnet M, Gibelin H, Brunaud L, Loudot C,Kraimps JL,Hamy A, BreslerL, Charbonnel B, Leborgne J, Henry JF, Nguyen JM, Mirallie E. Prospec­tive evaluation of quality of life (SF-36v2) and non­specific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery. 2007;141(2):153–9.
22. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22(6):513–8.
233
PRESENTATION AND DIAGNOSIS OF PRIMARY HYPERPARATHYROIDISM
23. Sadler GP, Mihai R, Jeevan D. Pasieka’s parathyroid symptoms scores correlate with SF-36 scores in patients undergoing parathyroidectomy for primary hyperpar­athyroidism. International surgical week 2007 Abstract
073.
24. Pasieka JL, Parsons LL, Demeure MJ, Wilson S, Malycha P, Jones J, et al. A patient-based surgical outcome tool demonstrating improvement of symptoms following parathyroidectomy in patients with primary hyperpar­athyroidism. World J Surg. 2002;26:942–9.
25. Sywak MS,Knowlton ST,Pasieka JL, ParsonsLL, JonesJ. Do the National Institutes of Health consensus guide­lines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyper­parathyroidism? Surgery. 2002;132(6):1013–9.
26. Grey A, Evans M, Stapleton J, Reid I.Body weight andbone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Int Med. 1994;121(10):745–9.
27. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe – nationwide cohort analysis on mortality from nonmalignant causes. J Bone Min Res. 2002;17 (Suppl 2):N68–74.
28. Lundgren E, LindL, PalmerM, JakobssonS, Ljunghall S, Rastad J. Increased cardiovascular mortality and nor­malized serum calcium in patients with mild hypercal­cemia followed up for 25 years. Surgery. 2001;130(6): 978–85.
29. Hagstrom E, Lundgren E, Mallmin H, Rastad J, Hellman P. Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyr­oidism. J Int Med. 2006;259(2):191–8.
30. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljun­ghall S, Hellman P, Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperpar­athyroidism: population-based study over five years. Clin Endocrinol. 2002;56(2):253–60.
31. Valdemarsson S, Lindblom P, Bergenfelz A. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Int Med. 1998;244(3):241–9.
32. Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92(5):1687–92.
33. Silverberg SJ, ShaneE, Jacobs TP, Siris ES, Gartenberg F, Seldin D, ClemensTL, BilezikianJP. Nephrolithiasisand bone involvement in primary hyperparathyroidism. Am J Med. 1990;89(3):327–34.
34. Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Int Med. 1975;83(3):365–7.
35. Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Heath H 3rd. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Int Med. 1992;152(11): 2269–73.
36. Dempster DW, Muller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ,Bilezikian JP. Preserved three­dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 2007;41(1):19–24.
37. Parisien M, Cosman F, Mellish RW, Schnitzer M, Nieves J, Silverberg SJ, Shane E, Kimmel D, Recker RR, Bilezi­kian JP et al. Bone structure in postmenopausal hyper­parathyroid, osteoporotic, and normal women. J Bone Min Res. 1995;10(9):1393–9.
38. VanderWalde LH, Liu IL, O’Connell TX, Haigh PI. The effect of parathyroidectomy on bone fracture risk in patients with primary hyperparathyroidism. Arch Surg. 2006;141(9):885–9.
39. Gardner EC Jr, Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. Southern Med J. 1981;74(2):197–9.
40. Mowat E, Gunn A, Paterson CR. Hyperparathyroidism in peptic ulcer patients. BJS. 1981;68(7):455–8
41. Gardner EC Jr, Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. Southern Med J. 1981; 74(2):197–9.
42. Bess M, Edis A, Von Heerden J. Hyperparathyroidism and pancreatitis. Chance or a causal association? JAMA. 1980;243:246–7.
43. Shepherd J. Hyperparathyroidism presenting as pan­creatitis or complicated by postoperative pancreatitis. Aust NZ J Surg. 1996;66:85–7.
44. Carnaille B, Oudar C, Pattou F, Combemale F, Rocha J, Proye C. Pancreatitis and primary hyperparathyroid­ism: forty cases. Aust NZ J Surg. 1998;68:117–9.
45. Caroll M, Schade D. A practical approach to hypercal­caemia. Am Fam Physician. 2003;67(9):1959–66.
46. Kebebew E, Clark O. Parathyroid adenoma, hyperplasia, and carcinoma. Surg Oncol Clin North Am. 1998;7: 721–48.
47. Binstock ML, Mundy GR. Effect of calcitonin and glu­cocorticoids in combination on the hypercalcaemia of malignancy. Ann Intern Med. 1980;87:269–72.
48. Lew J, Solorzano C, Irvin G. Long term results of para­thyroidectomy for hypercalcaemic crisis. Arch Surg. 2006;141:696–9.
49. Ziegler R. Hypercalcaemic crisis. J Am Soc Nephrol. 2001;12:S3–9.
50. Inabnet W, Lee J, Henry JF, Sebag F. Parathyroid dis­ease. In: Lennard T, ed., A companion to specialist surgical practice: endocrine surgery, 3rd ed. Amster­dam: Elsevier Saunders, 2006;6–8.
51. Major PP, ColemanRE. Zoledronic acid inthe treatment of hypercalcaemia of malignancy: results of the interna­tional clinical development program. Semin Oncol 2001;28(2 suppl 7):17–24.
52. Silva OL, Becker KL. Salmon calcitonin in the treat­ment of hypercalcaemia. Arch Int Med. 1973;132: 337–9.
53. Binstock ML, Mundy GR. Effect of calcitonin and glu­cocorticoids in combination on the hypercalcaemia of malignancy. Ann Int Med. 1980;93:269–72.
54. Rodriguez A, Trujillo MJ, Herrero T, et al. Allergy to calcitonin. Allergy. 2001;58:801.
55. Davidson TG. Conventional management of hypercal­caemia of malignancy. Am J Health-System Pharm. 2001;58(suppl 3):S8–15.
56. Lukert BP, Raisz LG. Glucocorticoid-induced osteo­porosis: pathogenesis and management. Ann Intern Med. 1990;112:352–64.
57. Strumpf M, Kowalski MA, Mundy GR. Effects of gluco­corticoids on osteoclas-activating factor. J Lab Clin Med. 1978;92:772–8.
234
ENDOCRINE SURGERY
58. Tisell L, Hedback G, Jansson S, Lindtstedt G, Zachrisson B. Management of hyperparathyroid patients with grave hypercalcaemia. World J of Surg. 1991;15:730–7.
59. Lew J, Solorzano C, Irvin G. Long term results of para­thyroidectomy for hypercalcaemic crisis. Arch Surg. 2006;141:696–9.
60. Monchik J, Gorgun E. Normocalcaemic hyperparathyr­oidism in patients with osteoporosis. Surgery. 2004;136: 1242–6.
61. Mather HG. Hyperparathyroidism with normal serum calcium. BMJ. 1953;2:424–5.
62. Maruani G, Hurtig A, Paillard M, Houillier P. Normo­calcaemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hor­mone. J Clin Endocrinol Metab. 2003;88:4641–8.
63. Lowe H, McMahonJ, Rubin M, Bilezikian J, Silvergerg S. Normocalcaemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001–5.
64. Hagstrom E, Lundgren E, Rastad J, Hellman P. Meta­bolic abnormalities in patients with normocalcaemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155:33–9.
65. Poole Jr GV, Albertson AD, Myers RT. Normocalcaemic hyperparathyroidism revisited. Am Surg. 1983;49:668–71.
66. Hagag P, Revet-Zak I, Hod N et al. Diagnosis of normo­calcaemic hyperparathyroidism by oral calcium loading test. J Endocrinol Invest. 2003;26(4):327–32.
67. Monchick JM. Normocalcaemic hyperparathyroidism. Surgery. 1995;118(6):917–23.
68. Payne, M. Albumin-adjusted calcium. Med Lab Obs 2004; 36(5).
69. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab. 1986;56:572–81.
70. BrownEM,PollakM,SeidmanCE,etal.Calcium-ion­sensing cell-surface receptors. N Engl J Med. 1995; 333:234–40.
71. Khosla S, Ebelling PR, Firek AF, et al. Calcium infusion suggests a ‘set point’ abnormality of parathyroid gland function in familial benign hypercalcaeima and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab. 1993;76:715–20.
72. KIfor S, Moore FD Jr, Wang P, et al. Reduced immunos­taining for the extracellular Ca primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598–606.
73. Ariyan C, Sosa J. Assessment and management of patients with abnormal calcium. Crit Care Med. 2004;32 suppl:S146–54.
74. Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Pro­duction of parathyroid hormone by a malignant non­parathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab. 1993;76(5):1373–5.
75. Attie MF, Gill Jr JR, Stock JL, Spiegel AM, Downs Jr RW, Levine MA, Marx SJ. Urinary calciumexcretion infamil­ial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest. 1983 August; 72(2): 667–76.
76. Vieweg J, Teh C, Freed K, Leder RA, Smith RH, Nelson RH, et al. Unenhanced helical computerized tomogra­phy for theevaluation ofpatients withacute flankpain. J Urol. 1998;160(3 Pt 1):679–84.
77. Sinclair D, Wilson S, ToiA, GreenspanL. Theevaluation of suspected renal colic: ultrasound scan versus excre­tory urography. Ann Emerg Med. 1989;18(5):556–9.
78. Erwin BC, Carroll BA, Sommer FG. Renal colic: the role of ultrasound in initial evaluation. Radiology. 1984;152(1):147–50.
79. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteo­porosis. Technical report series 843. Geneva: WHO, 1994.
80. KanisJA,DelmasP,BurckhardtP,CooperC,TorgersonD, on behalf of the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and manage­ment of osteoporosis. Osteoporosis Int 1997;7:390–406.
81. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000; 17(1): 1–36.
+2
-sensing receptor in
17

Parathyroid Localization and Imaging

Jean-Franc¸ois Henry, David Taı¨eb and Sam Van Slycke
Introduction
For many years bilateral cervical exploration with identification of four glands remained the gold standard in parathyroid surgery, and rou­tine preoperative imaging for initial surgery was considered unnecessary and not cost effective. In 1986, John L. Doppman stated ‘‘Inmy opinion, the only localizing study indicated in a patient with untreated primary hyperparathyroidism (HPT) is to localize an experienced parathyroid surgeon’’ [1]. Times have changed, and undoubt­edly it is the progress of imaging studies that has modified the surgical management of patients with HPT and helped the development of new surgical techniques.
Many imaging modalities have been reported. In the past, when only invasive localization procedures [angiography and selective venous sampling (SVS)] were available, localization of abnormal parathyroid glands was limited to reoperative cases. Today, the development and the reported efficacy of noninva­sive techniques have tempted many endocrinolo­gists and many surgeons to order some ofthese new noninvasive techniques on patients undergoing first-time parathyroidectomy.
Moreover, more than half the surgeons performing parathyroid surgery now consider that bilateral parathyroid exploration is no longer the only option in all patients with HPT. Patients presenting with solitary adenoma can be candidates for new focused surgical
procedures. This emphasizes the current role of preoperative localization studies in the surgi­cal management of patient with primary HPT.
After an overview of the various noninvasive tests and invasive tests currently used we will discuss the indications for each of them.
Preoperative Localization Tests
Noninvasive Tests
Ultrasonography
High-resolution ultrasonography (US) with a probe of 7.5 or 10 MHz is used in first-line para­thyroid imaging for many reasons.It iseasily and quickly performed, and well tolerated by the patient. It does not require administration of contrast medium and does not emit radiation. It provides good anatomic information about masses in the neck and, when performed by expert radiologists, 95% of adenomas that weigh in excess of 1,000 mg can be identified. In addition it is the least expensive preoperative localization technique. However US can only assess the cervical region.
The sensitivity of US is operator and material dependent. The patient should be examined in the supine position with the neck in hyperexten­sion. A pillow can be placed under the shoulders if the patient has a short neck. A high-frequency
J.G.H. Hubbard et al. (eds.), Endocrine Surgery, Springer Specialist Surgery Series, DOI 10.1007/978-1-84628-881-4_17, Ó Springer-Verlag London Limited 2009
235
linear transducer (7.5–10 MHz) is used to obtain optimal depth penetration of 3–4 cm. A bilateral and comparative scan should be performed in transverse section, then in longitudinal section. In transverse section, the examination concen­trates on an area defined by the longus colli muscles posteriorly, the thyroid gland ante­riorly, the trachea medially, and the carotid artery laterally. The scan is then performed in cranial and caudal directions. An additional scan can be performed with the head of the patient turned away to the side, and during deglutition to optimize the latero-esophageal images. The anterosuperior mediastinum is examined by inclining the transducer deeply in a retrosternal direction.
Enlarged parathyroid glands appear as a homogeneous well-demarcated mass, which is hypoechoic in contrast to the hyperechoic thyroid tissue. They are usually solid, but large adenomas may have a cystic component.
The examiner should note the precise loca­tion with respect to surrounding structures, particularly the thyroid gland, and the depth from the skin. Enlarged superior parathyroid glands are usually found adjacent to the poster­ior aspect of the thyroid lobe (Fig. 17.1). They tend to migrate posteriorly and in a downward direction (Fig. 17.2), sometimes into the pos­tero-superior mediastinum. Enlarged inferior
236
ENDOCRINE SURGERY
Fig. 17.2. Ultrasonography. Arrow 1: right thy roid lobe. Arrow 2:
superior or inferior parathyroid adenoma posterior to the inferior pole of the thyroid lobe.
parathyroid glands are usually found immedi­ately adjacent to the inferior pole of the thyroid lobes (Fig. 17.3). In 25% of cases, they are found at a variable distance from the lower pole of a thyroid lobe (Fig. 17.4). These adenomas, lying in the thyrothymic ligament or in the upper cervical portion of the thymus, remain located
Fig. 17.1. Ultrasonography. Arrow 1: right thyroid lobe. Arrow 2:
right superior parathyroid adenoma posterior to the two superior thirds of the thyroid lobe.
Fig. 17.3. Ultrasonography. Arrow 1: right thyroid lobe. Arrow 2:
right inferior parathyroid adenoma located just below the tip of the inferior pole of thyroid lobe and in the superficial plane.
237
PARATHYROID LOCALIZATION AND IMAGING
Fig. 17.4. Ultrasonography. Arrow 1: inferior pole of right
thyroid lobe. Arrow 2: right inferior parathyroid adenoma along thyrothymic ligament.
or the acoustic shadow of bone when located behind the clavicle or sternum. Sensitivity falls to 40% for reoperative localization since such patients have an increased incidence of ectopic mediastinal parathyroid adenomas or multi­glandular disease (MGD) [8].
Intrathyroid parathyroid adenomas are well imaged by US but they have an ultrasono­graphic appearance indistinguishable from that of hypoechoic thyroid nodules. As for other nonparathyroid anatomical structures, the diagnosis can be confirmed by US-directed fine needle aspiration (FNA) for parathyroid hormone (PTH) which is highly sensitive and specific [9–11]. False-positive results vary from 15 to 20% [12, 13].
Many factors may explain the variable reported accuracy of US, but it is likely that preoperative US localization is highly depen­dent on the skill and experience of the examiner. US is particularly useful when used in conjunc­tion with other modalities such as FNA and parathyroid scintigraphy.
superficially in the neck or in the superior med­iastinum. Some inferior adenomas located at the posterolateral part of the inferior pole of the thyroid lobe tend to migrate posteriorly (Fig. 17.2) and in a downward direction, and are found in a paratracheal or a paraesophageal position. US provides good anatomic detail that permits the surgeon to know the exact location of the adenoma in the neck and make a judi­cious choice of surgical access.
Finally, a color-flow Doppler or a power-flow Doppler is performed to test the vascularization of the area and define the artery branches involved.
In patients without prior parathyroid sur­gery, US has been shown to have sensitivity and a specificity of 70–85% and 90–95%, respec­tively [2–5]. The sensitivity is highly dependent on the size of the parathyroid gland. The limit of detection is approximately 5 mm. Fewer than 50% of adenomas weighing less than 200 mg are identified by US. This can explain the reduced accuracy of US in the presence of parathyroid hyperplasia, in which enlargement of individual glands may be minimal [6, 7]. Other common causes of false-negative examinations include associated multinodular goiter, adenomas located in the tracheoesophageal groove which can be obscured by the acoustic shadow of the trachea,
Parathyroid Scintigraphy
Over recent decades, several protocols of parathyroid scintigraphy have been evaluated [14–16]. imaging since the introduction of because of the poorer quality images and unfavor­able dosimetry.
use of
isonitrile), a lipophilic compound, is radiolabeled with philized kits. Following injection, the radiophar­maceutical is rapidly and passively accumulated within the mitochondria of metabolically active cells, including thyroid and parathyroid cells. Tracer retention is dependent on several factors such as mitochondria content, cell cycle, and expression of P-glycoprotein efflux protein. Two protocols for sestamibi scanning are in current use: the single isotope-dual phase protocol and the subtraction protocol.
cept of single radiopharmaceutical/dual phase imaging [18]. This approach is based on the differential sestamibi retention between para­thyroid and thyroid tissue. After injection of
99m
201
Tl has been abandoned in parathyroid
Coakley and coworkers first reported on the
99m
Tc-sestamibi for parathyroid
99m
Tc-sestamibi
imaging [17]. Sestamibi (methoxy-isobutyl-
99m
Tc-pertechnetate, using commercial lyo-
Taillefer and coworkers introduced the con-
Tc-sestamibi, tracer retention is prolonged
238
ENDOCRINE SURGERY
in parathyroid hyperfunctioning lesions whereas it washes out more rapidly from normal thyroid tissue. This retention is presumably related to oxyphil cells in parathyroid lesions which are rich in mitochondria. The dual protocol requires early (15 min postinjection) and delayed images (at 1 and 2–3 h, depending on thyroid washout). Image acquisition is centered over the 140 Kev photopeak. On the early images, activity of the parathyroid lesion may be more intense, intense as, or less intense than thyroid activity. The detectability of disease is dependent on parathyr­oid–thyroid activity ratio and location of the tumour. On the delayed images, parathyroid lesions are easily identified (Fig. 17.5). However, washout of parathyroid lesions compared to thyroid may vary between subjects.
This technique is easy and simple, but has some specific limits such as parathyroid adeno­mas that clear sestamibi, low mitochondrial content (hyperplastic glands), and abnormal tracer retention in thyroid nodules (hyperfunc­tioning nodules, cancer). In cases of multinod­ular thyroid disease, additional further delayed images are sometimes needed to overcome these pitfalls.
When a subtraction protocol is used,
99m
Tc-sestamibi is used in conjunction with
another radionuclide specific to the thyroid.
99m
Tc-pertechnetate and
used radioisotopes for thyroid scintigraphy.
99m
Tc-pertechnetate is obtained from generators, has a half-life of 6 h and emits a 140-Kev gamma ray.
123
I are the most widely
99Mo/99m
123
I is cyclotron produced,
Tc
has a half-life of 13 h, and a gamma ray emission of 159 Kev. Both tracers are concentrated in thyrocytes via NIS protein but only nified in thyroid follicles.
The main advantage of using
123
Iisorga-
123
I is that thyroid and parathyroid images can be acquired simultaneously in a dual energy window set up. The disadvantage is the increased cost of the protocol related to 2–4 h before acquisition. With
123I.123
I is usually injected
99m
Tc-pertech­netate, the thyroid image can be acquired either before or after the completion of sestamibi acqui­sition. When
99m
Tc-pertechnetate is injected after sestamibi acquisition, both the dual phase protocol and the subtraction protocol can be performed. After normalization, thyroid images are digitally subtracted from sestamibi images. The residual image corresponds to an image of
Fig. 17.5. Dual phase protocol: injection of 740 of
static images at 15, 60, 120, and 180 min. The images shows more delayed washout of (white arrow) than from the normal thyroid, resulting in increase contrast. A parallel hole collimator was used.
99m
Tc-sestamibi at T0. Dynamic planar images (from 1 to 10 min postinjection),
99m
Tc-sestamibi from the parathyroid lesion
239
PARATHYROID LOCALIZATION AND IMAGING
Ior
123
I at T–2h, injection of 740 of
prolapsed behind the lower pole of the thyroid gland. These adenomas can be located very deeply in the neck, in paraesophageal or retro­esophageal locations, that may be missed by inexperienced surgeons (Figs. 17.7 and 17.8). By contrast, inferior glands are mostly located at the tip of the inferior pole of the thyroid lobe or along
99m
the thyrothymic tract on planar images and remain anterior on SPECT imaging (Fig. 17.9).
Tc-
SPECT also enables a better localization of large adenomas prolapsed in the mediastinum and ectopic glands (Figs. 17.10 and 17.11). There is no consensus regarding the timing of SPECT acquisition. Our preference is to perform SPECT 45–60 min after there is sufficient residual activity in thyroid for determining the relative position of parathyroid adenomas. Finally, the use of SPECT–CT fusion images is particularly helpful for localizing ectopic glands (Fig. 17.12).
There is no consensus regarding which imaging protocol should be used. The subtrac­tion method seems to have a higher sensitivity than dual phase imaging [20–24]. However, only a few studies have compared both proce-
Fig. 17.6. Subtraction protocol: injection of 12 MBq of
pinhole acquisition at T + 3 (20 min acquisition). A typical example of parathyroid adenoma. (A) image. (B) The lesion in the right lower pole of the thyroid. Simple visual comparison of two images is unable to reveal differences in tracer distribution. The detection of the adenoma needs digital subtraction of images (after normalization of thyroid image).
123
I scan shows a normal thyroid gland. (C) The subtraction image (
the parathyroid. Simple visual comparison of two images can also reveal differences in tracer distribution, but the detection of small lesions needs the computer manipulation of images (Fig. 17.6). When using two separate acquisitions for both isotopes, patient movement between data acquisitions may lead to false-positive images. Another potential pitfall of the subtrac­tion protocol is reduced or absent
123
pertechnetate thyroid uptake, which renders the subtraction image invalid.
Parathyroid scintigraphy should include views of the neck and the mediastinum (from the angle of the mandible to the heart) because ectopic glands are widely distributed along the parathyroid cell migration routes.
The type of collimator used can affect the sensitivity of the procedure. The parallel hole collimator enables simultaneous imaging of both neck and mediastinum. The pinhole colli­mator provides higher resolution images and magnifies the structure being imaged. However, the field of view is smaller than for the parallel hole collimator, and images of the neck and mediastinum should be obtained separately.
99m
Tc-sestamibi-
99m
99m
Tc-sestamibi at T0, dual tracer planar
99m
Tc-sestamibi pinhole planar
123
I) demonstrates a parathyroid
Tc-sestamibi injection because
duresinanintrapatientanalysis.Thereported
Single-Photon Emission Tomography
Single-photon emission tomography (SPECT) or anterior oblique views can be helpful for more precise localization of adenomas. SPECT provides simultaneous 3D information on both the neck and the mediastinum. There is a further improvement in sensitivity and image quality when iterative reconstruction is used instead of filtered back-projection [19]. SPECT is particularly useful for reclassifying apparently inferior adenomas to superior adenomas
sensitivity of parathyroid scintigraphy ranges from 70 to 100%, and mainly depends upon gland weight and PTH values, but is not related to calcium levels. SPECT may provide improvement in sensitivity in comparison to planar imaging [25–29]. In our experience, sensitivity reaches 90% when PTH >150 ng/ ml or gland weight >1,000 mg, with only mar­ginal improvement in sensitivity with SPECT [30]. In smaller lesions, sensitivity may vary between tumors.